Ionis Pharmaceuticals (MEX:IONS) Inventories, Finished Goods: MXN18 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
67 GF Score
Price MXN1,150.00
GF Value MXN757.76
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Inventories, Finished Goods?

Ionis Pharmaceuticals MEX:IONS 67 Inventories, Finished Goods is MXN18 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 67/100 and a GF Value™ of MXN757.76. The stock has 8 warning signs investors should review.

Ionis Pharmaceuticals's quarterly finished goods increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN20 Mil) but then declined from Dec. 2025 (MXN20 Mil) to Mar. 2026 (MXN18 Mil).

Ionis Pharmaceuticals's annual finished goods increased from Dec. 2023 (MXN3 Mil) to Dec. 2024 (MXN6 Mil) and increased from Dec. 2024 (MXN6 Mil) to Dec. 2025 (MXN20 Mil).

Ionis Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Inventories, Finished Goods Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 3.20 2.61 5.76 19.73

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.33 0.00 0.00 19.73 17.85
MEX:IONS
67GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN18 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Inventories, Finished Goods of MXN18 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Inventories, Finished Goods too high?
Ionis Pharmaceuticals' current Inventories, Finished Goods is MXN18 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Inventories, Finished Goods compare to EXEL and BBIO?
Ionis Pharmaceuticals' Inventories, Finished Goods of MXN18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Inventories, Finished Goods is MXN18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Inventories, Finished Goods of MXN18 Mil. The stock's GF Value™ is MXN757.76, compared to a current price of MXN1,150.00 — trading 51.8% above its estimated fair value. The current Inventories, Finished Goods is MXN18 Mil. Ionis Pharmaceuticals' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Inventories, Finished Goods is MXN18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 51.8% above its estimated GF Value™ of MXN757.76.

Key valuation signals for MEX:IONS:

  • Inventories, Finished Goods: MXN18 Mil
  • GF Value™: MXN757.76 vs. price of MXN1,150.00 (51.8% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
67GF Score

Get the complete analysis for MEX:IONS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN757.76
GF Value